Anzeige
Mehr »
Samstag, 19.07.2025 - Börsentäglich über 12.000 News
Kupfer en mass...: 10 Prozent-Kupfer an der Oberfläche! - Diese Entdeckung könnte zur heißesten Kupferstory des Jahres werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB6B | ISIN: US26818M1080 | Ticker-Symbol:
NASDAQ
18.07.25 | 21:59
9,020 US-Dollar
-3,94 % -0,370
1-Jahres-Chart
DYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiHedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More26
MiDyne shares up after CEO buys stock3
02.07.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares2
DYNE THERAPEUTICS Aktie jetzt für 0€ handeln
02.07.Bernstein lowers Dyne Therapeutics stock price target on equity raise3
01.07.Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr369WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25...
► Artikel lesen
01.07.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock8
30.06.Dyne Therapeutics sichert sich Kreditfazilität von 275 Millionen US-Dollar von Hercules Capital14
30.06.Dyne Therapeutics announces public offering of common stock1
30.06.Dyne Therapeutics secures $275 million loan facility from Hercules Capital9
30.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Proposed Public Offering of Common Stock2
30.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital9
30.06.Dyne Therapeutics, Inc. - 8-K, Current Report2
25.06.Jones Trading initiates Dyne Therapeutics stock with buy rating1
25.06.Jones Trading startet Dyne Therapeutics-Aktienabdeckung mit Kaufempfehlung1
18.06.H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock3
17.06.Dyne falls amid delay in clinical program for muscle disorder therapy2
17.06.Dyne Therapeutics stock falls after updated plan for accelerated approval in DM13
17.06.Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint414WASHINGTON (dpa-AFX) - Dyne Therapeutics (DYN) announced the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of myotonic dystrophy type 1. The company also announced...
► Artikel lesen
17.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting173- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase...
► Artikel lesen
17.06.Dyne Therapeutics, Inc. - 8-K, Current Report3
Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1